- PTC518 demonstrated dose-dependent reduction of HTT mRNA in preliminary results from Phase 1 healthy volunteer trial -
- Total net revenue of $118 million; 73% increase over first quarter 2020 -
- DMD franchise net product revenue of $90 million; 32% increase over first quarter 2020 -
- PTC has clinical trials ongoing in multiple disease areas, three of which are registration-directed studies -
PR Newswire
SOUTH PLAINFIELD, N.J., May 4, 2021